A message to Generex: Generex has suffered a nu

A message to Generex:

Generex has suffered a number of setbacks recently. While setbacks in business are a reality, the number of issues with Generex and severity of these issues have shaken confidence in the companies operations.

Friday's conference call provides Generex with the opportunity to update investors regarding current happenings and future initiatives.


I would like to know:

The exact status of Generex's NAZ application as of 11/27/19. What qualification(s) are we short? What is the plan for completing anything we do not yet meet?

What date Generex found out about CMF selling
How Generex found out about CMF selling
What regulatory agency(s) have been notified, what date were they notified and did Generex receive a response stating the agency rec'd the notification. I would appreciate having the information posted on the Generex website.


Is Generex aware of any other selling of shares by entities or individuals associated with those entities Generex has acquired?

In a previous CC, Joe stated he was considering action looking into unusual market activity in GNBT's trading. Illegal shorting perhaps being a concern etc. What steps have been taken in this regard?

I would appreciate every single one of the companies having their CEO be on this call and individually assure investors they are 100% committed to Generex and it's vision for the future. Basically a vote of confidence.

I would particularly like Dr Patel to be on the call and provide his vision for the projects he is pursuing with Generex providing confirmation of his involvement and support moving forward. Given his standing, I can think of nothing better to help restore my confidence we are on the right track.

Public company purchase/NGIO merger/exchange listing and trading details including valuation information.

I welcome ALTuCELL into the Generex family. I am very excited for this technology to transform the lives of patients with diabetes. I look forward to the team at ALTuCell along with Dr Anderson and his team to forward Generex's established platform. An explanation of the steps and estimated timeframe to transform ALTuCELL from a company valued(for acquisition purposes) at $29.5M to a $950M plus valuation based on the repeated comparison to Semma would be appreciated considering the markets lack of response to this incredible acquisition.

I would like Generex to provide to it's employees/insiders etc with a defined benefit plan allowing them to purchase on the open market common stock should they choose. I have sent Generex general information from an extremely well respected source multiple times and to various parties on how this can be accomplished regardless of pending news etc. (Rule 10b5-1 Plans) This can be set up with little energy or expense to Generex and should also be set up for new entities prior to their becoming public so insiders/employees can have benefit as part of their compensation package.

Did Generex obtain the$10M non dilutive loan from the bank? Is part of that money being used to fund the monies due ALTuCELL next month at the purchase closing?